Vertex Pharmaceuticals shares rise 17% in 2027 on strong Q3 sales and institutional buying.

Vertex Pharmaceuticals reported a 12% year-over-year revenue increase to $3.44 billion in Q3 2027, driven by cystic fibrosis and new products. Despite a slight dip in non-GAAP earnings per share, the company raised its full-year revenue guidance to $13.25 billion. Institutional investors have shown strong and sustained buying interest in 2026, pushing shares up 24.6% over the year. With solid sales growth, profit margins, and expected EPS growth, Vertex remains a compelling stock for investors seeking growth in healthcare biotech.

Vertex Pharmaceuticals holds a market cap of $134.53 billion and an enterprise value of $128.65 billion as of Nov 04, 2026 18:42 WIB. On Pluang, the stock trades at USD 536.35 with a 1-day gain of 1.05%, reflecting steady investor interest despite a 58% sell order activity. The typical holding period on Pluang is 123 days, indicating moderate-term confidence in the healthcare biotech sector.